<DOC>
	<DOCNO>NCT00003356</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Interleukin-2 may stimulate person 's white blood cell kill cancer cell . PURPOSE : Phase I/II trial study effectiveness combine rituximab interleukin-2 intreating patient low-grade mantle cell lymphoma follicular lymphoma .</brief_summary>
	<brief_title>Rituximab Plus Interleukin-2 Treating Patients With Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient low-grade , mantle cell , follicular B-cell lymphoma treat combination rituximab low-dose interleukin-2 ( IL-2 ) . II . Determine maximum tolerate dose IL-2 give conjunction rituximab patient population . III . Assess whether antibody dependent cellular cytotoxicity ( ADCC ) enhance vivo exposure IL-2 whether ADCC activity correlate clinical response patient . IV . Assess incidence antirituximab antibody formation patient . OUTLINE : Patients receive interleukin-2 ( IL-2 ) subcutaneously day 1-5 rituximab IV day 3 . Courses repeat weekly 4 week absence disease progression unacceptable toxicity . Patients follow weekly 4 week every 3 month 1 year . PROJECTED ACCRUAL : A total 14-29 patient low-grade/follicular lymphoma 14-29 patient mantle cell lymphoma accrue study within 2-5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIIV lowgrade , mantle cell , follicular Bcell lymphoma Stage I disease eligible radiotherapy consider feasible due location disease previous radiation treatment No chronic lymphocytic lymphoma No small lymphocytic lymphoma lymphocyte count great 5,000/mm3 Must either firstline therapy 4 relapse standard therapy , include chemotherapy , radiotherapy , autologous bone marrow transplantation , and/or immunotherapy Eligible refractory first treatment standard therapy Patients refractory autologous bone marrow transplantation ( ABMT ) relapse ABMT eligible Patients lowgrade follicular lymphoma must fail least one chemotherapy regimen Patients mantle cell lymphoma eligible even prior treatment Bidimensionally measurable disease Demonstrable monoclonal CD20positive Bcell population lymph node bone marrow No prior diagnosis intermediate highgrade nonHodgkin 's lymphoma No CNS , pericardial , pleural , peritoneal involvement lymphoma No AIDSrelated lymphoma No pleural effusion No ascites A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 75 Performance status : ECOG 02 Life expectancy : At least 4 month Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 75,000/mm3 Hemoglobin least 8.0 g/dL Hepatic : Bilirubin great 2.0 mg/dL Alkaline phosphatase great 2 time upper limit normal ( ULN ) SGOT great 2 time ULN Renal : Creatinine clearance least 65 mL/min Cardiovascular : See Disease Characteristics No pericardial effusion No New York Heart Association class III IV heart disease No myocardial infarction within past 6 month Other : No active , uncontrolled bacterial , viral , fungal infection No active opportunistic infection No active inflammatory arthritis ( exclude degenerative joint disease ) No know hypersensitivity interleukin2 No history autoimmune disorder No history seizure disorder No primary malignancy past 5 year except squamous cell basal cell carcinoma skin carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior radioimmunotherapy At least 6 month since prior autologous bone marrow transplantation recover At least 4 week since prior colonystimulating factor epoetin alfa At least 3 week since prior immunotherapy recover No concurrent hematopoietic growth factor Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week nitrosourea mitomycin ) recover Endocrine therapy : At least 3 week since prior corticosteroid No corticosteroid 8 week study Radiotherapy : See Disease Characteristics See Biologic therapy At least 3 week since prior radiotherapy recover Surgery : Not recipient allogeneic organ transplantation , unless organ long functional At least 4 week since prior major surgery ( except diagnostic surgery ) recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>